Report
Nyxoah - Q1 in line with expectations
Nyxoah published its Q1 24 results. Revenues were in line with CSS, up 177% YoY. Remember that management guided for a 25% decline in Q1 sales following a seasonality effect in Q4. We should also see more effects from the ResMed partnership as of H2.Stock has been hit recently as the market awaits a capital raise. Management previously indicated that they would raise capital on the back of the DREAM trial results Yet, the company still has cash until the end of the year. Next key catalyst is of course the FDA approval foreseen by year end. We allocate a
Underlying
Nyxoah
Provider
Degroof Petercam
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
Laura Roba
Other Reports on these Companies
Other Reports from Degroof Petercam
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.